- Research data accumulated over the past 20 years translated into AI algorithm

- New platform is expected to significantly cut down the time and cost required for the discovery of new drug candidates

 

SK Biopharmaceuticals (CEO Jeong Woo Cho, www.skbp.com) announced that it has completed the development of ‘AI Drug Design Platform.’

 

Through a collaboration with SK Holdings C&C, the SK Biopharmaceuticals developed the platform with an AI algorithm optimized for new drug development based on extensive research data and researchers' actual experience in the central nervous system that the company has accumulated over more than 20 years.

 

SK Biopharmaceuticals' AI drug design platform technology consists of ▲AI Model (drug property prediction / drug design), ▲ Compound Data Repository and ▲AI Model Repository.
 

The AI ​​Model was developed through the machine learning and deep running techniques of SK Holdings C & C. The model consists of a ‘drug property prediction model’ ­-- which enables researchers to study a new compound’s ADMET profile (absorption, distribution, metabolism, excretion, toxicity) and the mechanism of action of the drug candidate -- and a ‘drug design' model that uses predictive results to identify the properties of drugs in the data and design and propose new compounds.

 

While the ‘drug property prediction’ system has been widely used in Korea, researchers can now make a prediction and even design new compounds that are patentable using SK Biopharmaceuticals’ drug design platform.

 

The Compound Data Repository collects internal and external data containing experimental information and patent information of compounds, and processes them into AI data that researchers can use and search. In the AI Model Repository, the latest learning data provided by the Compound Data Repository constantly upgrades the AI Model.

 

Researchers at SK Biopharmaceuticals will be able to efficiently search for and design new drug candidates, and present research hypotheses using the newly developed 'AI-based drug design platform' along with the SKBP Discovery Portal System.

 

"The unique AI platform enables us to predict and design new compounds. Through the platform, we expect to shorten the time and cost it takes to develop a new drug by accelerating the process of finding promising new drug candidates," said Cheol-Young Maeng, head of the Digital Healthcare Task Force Team at SK Biopharmaceuticals.

 

"We hope that the efficiency of new drug development for SK Biopharmaceuticals researchers will be enhanced through the drug design platform. We will try our best to make Aibril* perform various roles in the domestic pharmaceutical industry," said Jun Hwan Kim, head of the Platform & Tech1 Group at SK Holdings C&C.

 

Meanwhile, SK Biopharmaceuticals and SK Holdings C&C are considering making the platform a shared infrastructure to contribute to the advancement of Korean pharmaceutical industry.

 

*Aibril: AI service developed by SK Holdings C&C